Company:

News and Publications

FOR IMMEDIATE RELEASE

For more information contact:
Stephanie Stiles, Director of Marketing
phone: 781.273.5480
sstiles@putassoc.com

John A. Gordon to Speak on Panel
at MIT Sloan BioInnovations 2011 Annual Health Care Conference
What challenges keep our health care leaders up at night and
what opportunities motivate them each morning?

March 3, 2011 -- Putnam Associates, a Boston-based strategy consulting firm serving the biotechnology and pharmaceutical industries globally, is pleased to announce that John A. Gordon, Partner, will be a panelist at the MIT Sloan BioInnovations 2011 Annual Health Care Conference, held on Friday, March 4, 2011, 8:30 a.m. — 4:00 p.m. at Boston Marriott Cambridge Hotel, Kendall Square, Cambridge, MA.

John Gordon will be a speaker on the panel entitled, “Regulatory Uncertainty,” taking place at 10:00 a.m. — 11:30 a.m. In addition to Mr. Gordon, panelists include: Michael Del Aguila, Senior VP, Genentech; Gregory Simon, Senior VP, Pfizer; and Heather Steinfield, Partner, Simon-Kucher & Partners (moderator).

Keynote speakers are Peter Hecht, Ph.D., CEO, Ironwood Pharmaceuticals; Steve Rusckowski, CEO, Philips Healthcare and Executive VP, Royal Philips Electronics; and Harvey J. Berger, M.D., Chairman and Chief Executive Officer, ARIAD Pharmaceuticals..

The panel discussion will address:

  • Implications to providers and industry on evolving regulatory standards
  • Impact of comparative effectiveness studies on all healthcare stakeholders
  • Challenges and benefits of value-based clinical guidelines
  • Role of personalized medicine in driving value-based medicine

John Gordon has been with Putnam Associates since 1992, and has over 21 years of strategy consulting experience. For more than 18 years, he has counseled senior executives at numerous leading pharmaceutical and biotechnology companies, providing strategic support and recommendations on a wide array of issues, including pricing and reimbursement, health economics and outcomes research, new product commercialization, clinical trial development, and sales force optimization strategies. John has extensive experience in specialty pharmaceutical markets that comprise Oncology, Immunology, Cardiovascular Disease, and Anti-Infectives. He is published in peer-review literature as a co-author on a study examining the cost effectiveness of a novel immunological agent used in solid organ transplantation. John was moderator and speaker for the biotechnology and pharmaceutical panel at Harvard Business School’s 2010 Annual Healthcare Conference on the topic, “How Will IP Shape Growth?” Prior to joining Putnam, John worked for an economics consulting firm providing expert testimony in matters of corporate and personal litigation. Currently, John serves on the Board of Directors for the National Tay-Sachs & Allied Diseases Association, Inc. John earned a BA in Economics summa cum laude, phi beta kappa from Tufts University and an MBA from Harvard Business School.

Putnam Associates (www.putassoc.com) is a strategy consulting firm headquartered in Boston, founded in 1988, advising the pharmaceutical, biotechnology, diagnostics, and medical device industries on a global basis. Two decades of experience and focus in their industries enable them to create significant value for their clients. Creative and disciplined strategy development processes blend with deep market knowledge for one purpose: to help their clients succeed. The company's partnership includes: Kevin J. Gorman, Managing Partner (BA, Boston College; MBA, Harvard Business School); John A. Gordon, Partner (BA, summa cum laude, Tufts University; MBA, Harvard Business School); Eric C. Auger, Partner (BA, Providence College; MA, Boston University); and Domenick Bertelli, Partner (AB, Harvard University; MBA, MIT Sloan School of Management); Remco op den Kelder, Partner (BA, Fontys University; MSc, University of Strathclyde); Paul Bogorad, Partner (BA, Swarthmore College; MBA, Columbia Business School; Ph.D., Princeton University).

###